Welcome to our dedicated page for enGene Therapeutics news (Ticker: ENGN), a resource for investors and traders seeking the latest updates and insights on enGene Therapeutics stock.
enGene Therapeutics Inc. develops non-viral genetic medicines for delivery to mucosal tissues and other organs. The company’s lead program is detalimogene voraplasmid, also known as detalimogene, for non-muscle invasive bladder cancer. Detalimogene is being evaluated in the multi-cohort LEGEND Phase 2 trial, including a pivotal cohort in high-risk, Bacillus Calmette-Guérin-unresponsive patients with carcinoma in situ, with or without concomitant papillary disease.
Recurring enGene news includes LEGEND clinical data, FDA designation and manufacturing-readiness updates, business and financial results, debt and equity financing activity, investor-conference participation, and corporate matters such as the completed name change from enGene Holdings Inc. to enGene Therapeutics Inc. The company’s common shares trade on Nasdaq under ENGN, and its listed warrants trade under ENGNW.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.